Comment on “Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies” and “High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints”

Currently, there is no evidence that unbound isavuconazole concentrations are a better predictor of treatment response than total concentrations. [...]clinical implementation of monitoring unbound isavuconazole concentrations in routine clinical practice is difficult to justify. While isavuconazole...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacokinetics Vol. 63; no. 5; pp. 731 - 733
Main Authors: Kong, Leping, Alffenaar, Jan-Willem C., Stocker, Sophie L.
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01.05.2024
Springer Nature B.V
Subjects:
Antibiotics
Biomarkers
Biosensors
Clinical medicine
Conflicts of interest
Drug dosages
Internal Medicine
Laboratories
Letter to the Editor
Medicine
Medicine & Public Health
Pharmaceutical industry
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Proteins
Real time
ISSN:0312-5963, 1179-1926, 1179-1926
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Currently, there is no evidence that unbound isavuconazole concentrations are a better predictor of treatment response than total concentrations. [...]clinical implementation of monitoring unbound isavuconazole concentrations in routine clinical practice is difficult to justify. While isavuconazole is highly protein bound, it has a low intrinsic clearance; therefore, changes in the fraction unbound are unlikely to impact its pharmacokinetics (specifically clearance). [...]we propose that the importance of measuring unbound isavuconazole concentrations, as a better predictor of treatment response, should be established before implementation of routine monitoring of free concentrations. [...]a better understanding of isavuconazole pharmacokinetics/pharmacodynamics and its unbound drug concentrations will have practical implications regarding how we perform therapeutic drug monitoring.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0312-5963
1179-1926
1179-1926
DOI:10.1007/s40262-024-01357-4